Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Gypenoside LXXV, derived from Gynostemma pentaphyllum, is a deglycosylated form of ginsenoside Rb1. This compound effectively decreases cancer cell viability and exhibits potent anti-cancer properties.
产品描述 | Gypenoside LXXV, derived from Gynostemma pentaphyllum, is a deglycosylated form of ginsenoside Rb1. This compound effectively decreases cancer cell viability and exhibits potent anti-cancer properties. |
体外活性 | Gypenoside LXXV (1.0-100 μM; for 48 hours) reduces proliferation in a dose-dependent manner[1]. Cell Viability Assay[1]Cell Line: Three cancer cell lines (HeLa (cervical cancer cell line), B16 (melanoma cell line), and MDA-MB231 (human breast cancer cell line) Concentration: 1.0-100 μM Incubation Time: For 48 hours Result: Reduced proliferation in a dose-dependent manner and inhibited almost all cancer cells at 50 μM. |
分子量 | 785.025 |
分子式 | C42H72O13 |
CAS No. | 110261-98-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Gypenoside LXXV 110261-98-8 Inhibitor inhibitor inhibit